Cycloferon

I. Assessment

A. Policy and Research Question

Policy Question:

Should the Philippine government accept the donation and introduce MA as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31?

       Research Questions:

      1. What is the market entry status of MA across different countries? What are the current country TGs or CPGs which recommend the use of MA in treating patients with COVID-19?
      2. What is the clinical efficacy/ effectiveness and safety of MA as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31? [primary] What is the clinical efficacy/effectiveness and safety of MA as an add-on to supportive treatment for patients with influenza versus the DOH-PSMID recommended guidelines as of March 31? [secondary]
      3. Does MA as an add-on to the DOH-PSMID-recommended treatment regimens represent value for money for patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31?

B. Protocol: Not available.

C. Reviewers: Health Technology Assessment Unit, DOH

D. Start of Review:  March 24, 2020

E. End of Review:  April 7, 2020

II. Recommendation

Evidence summary:  https://bit.ly/ESCycloferon

Rapid review: https://bit.ly/RRCycloferon

III. Decision

Not available.